scholarly journals Destined to die in hospital? Systematic review and meta-analysis of place of death in haematological malignancy

2010 ◽  
Vol 9 (1) ◽  
Author(s):  
Debra A Howell ◽  
Eve Roman ◽  
Helen Cox ◽  
Alexandra G Smith ◽  
Russell Patmore ◽  
...  
Keyword(s):  
Systematic Review ◽  
Haematological Malignancy ◽  
Meta Analysis ◽  
Place Of Death

scholarly journals Preferred Place of Death in Adult Cancer Patients: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Armin Fereidouni ◽  
Maryam Rassouli ◽  
Mahmood Salesi ◽  
Hadis Ashrafizadeh ◽  
Amir Vahedian-Azimi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Confidence Interval ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Place Of Death ◽  
Related Factors ◽  
Factors Affecting ◽  
Relative Risks ◽  
Online Databases ◽  
Quality Of Death

Background: Identifying the preferred place of death is a key indicator of the quality of death in cancer patients and one of the most important issues for health service policymakers. This study was done to determine the preferred place of death and the factors affecting it for adult patients with cancer.Methods: In this systematic review and meta-analysis study four online databases (PubMed, Scopus, web of science, ProQuest) were searched by relevant keywords. Quality assessment of papers was conducted using Newcastle-Ottawa (NOS) criterion. Odds ratios, relative risks, and 95% confidence intervals were determined for each of the factors extracted from the investigations.Results: A total of 14,920 participants of 27 studies were included into the meta-analysis. Based on the results, 55% of cancer patients with a confidence interval [95% CI (41–49)] preferred home, 17% of patients with a confidence interval [95% CI (−12%) 23)] preferred hospital and 10% of patients with confidence interval [95% CI (13–18)] preferred hospices as their favored place to die. Effective factors were also reported in the form of demographic characteristics, disease-related factors and psychosocial factors.Conclusions: This study showed that more than half of cancer patients chose home as their preferred place of death. Therefore, guided policies need to ensure that the death of the patients in the preferred place should be considered with priority.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020218680, identifier: CRD42020218680.

scholarly journals Immunogenicity of COVID-19 vaccines in patients with haematological malignancy: A systematic review and meta-analysis

2021 ◽  
Author(s):  
Joanne S.K. Teh ◽  
Julien Coussement ◽  
Zoe C.F. Neoh ◽  
Tim Spelman ◽  
Smaro Lazarakis ◽  
...  
Keyword(s):  
Systematic Review ◽  
Immune Responses ◽  
Cellular Response ◽  
Haematological Malignancy ◽  
Meta Analysis ◽  
High Risk Patient ◽  
Seropositivity Rate ◽  
Dose Rates ◽  
Underlying Malignancy ◽  
Patient Groups

The objectives of this study were to assess the immunogenicity and safety of COVID-19 vaccines in patients with haematological malignancy. A systematic review and meta-analysis of clinical studies of immune responses to COVID-19 vaccination stratified by underlying malignancy and published from 1 January 2021 to 31 August 2021 was conducted using MEDLINE, EMBASE and CENTRAL. Primary outcome was the rate of seropositivity following 2 doses of COVID-19 vaccine with rates of seropositivity following 1 dose, rates of positive neutralising antibody (nAb), cellular responses and adverse events as secondary outcomes. Rates were pooled from single arm studies while rates of seropositivity were compared against the rate in healthy controls for comparator studies using a random effects model and expressed as a pooled odds ratio with 95% confidence intervals. Forty-four studies (16 mixed group, 28 disease specific) with 7064 patients were included in the analysis (2331 following first dose, 4733 following second dose). Overall seropositivity rates were 61-67% following 2 doses and 37-51% following 1 dose of COVID-19 vaccine. The lowest seropositivity rate was 51% in CLL patients and was highest in patients with acute leukaemia (93%). Following 1 dose, nAb and cellular response rates were 18-63% and 33-86% respectively. Active treatment, ongoing or recent treatment with targeted and CD-20 monoclonal antibody therapies within 12 months was associated with poor COVID-19 vaccine immune responses. New approaches to prevention are urgently required to reduce COVID-19 infection morbidity and mortality in high-risk patient groups that respond poorly to COVID-19 vaccination.

Haematological malignancy: are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data

2011 ◽  
Vol 25 (6) ◽  
pp. 630-641 ◽  
Author(s):  
Debra A Howell ◽  
Rhiannon Shellens ◽  
Eve Roman ◽  
Anne C Garry ◽  
Russell Patmore ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hospice Care ◽  
Haematological Malignancy ◽  
Meta Analysis ◽  
Published Data

The effects of low-ratio n-6/n-3 PUFA on biomarkers of inflammation: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Yali Wei ◽  
Yan Meng ◽  
Na Li ◽  
Qian Wang ◽  
Liyong Chen
Keyword(s):  
Systematic Review ◽  
Fatty Acid ◽  
Polyunsaturated Fatty Acid ◽  
Meta Analysis ◽  
Chain Polyunsaturated Fatty Acid ◽  
Inflammation Markers ◽  
Pufa Supplementation ◽  
Long Chain

The purpose of the systematic review and meta-analysis was to determine if low-ratio n-6/n-3 long-chain polyunsaturated fatty acid (PUFA) supplementation affects serum inflammation markers based on current studies.

Sign in / Sign up

Export Citation Format

Share Document